The temporary delicensing of the centrally acting appetite suppressants (first in April 2000, then in May 2001) by the European Commission's Committee on Proprietary Medical Products was premature and possibly unjustified. While their ultimate fate is awaited, the European Drugs Evaluation Agency declined to release the information on which its withdrawal advice was based.